Government ❯ Politics ❯ Regulatory Agencies

FDA

Drug Policy Public Health Drug Regulation Marty Makary Leadership Changes Vaccine Approval Process Drug Advertising Reproductive Rights Drug Approval Commissioner Actions E-Cigarette Regulation Leadership Issues Health Policy Healthcare Regulation Drug Safety Decision Making Public Health Policy Resignation Food Safety Mifepristone Drug Approval Process Abortion Regulations Tobacco Regulation Abortion Policy

FDA Advisory Panel Narrowly Backs Compounding of Six Unapproved Peptides

The vote puts the FDA on a decision path that must reconcile agency scientists’ safety warnings with industry pressure before any change becomes legal.

GOP Senators Press FDA on Illegal Online Abortion Pill Sales, Launch Probe of Mifepristone Makers

EU Regulators Back First Combined COVID-19 and Flu mRNA Shot for Adults 50 and Over

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

Missouri, Kansas and Idaho Sue to Block FDA’s New Generic Mifepristone Approval, Curb Mail-Order Access

FDA Approves Second Generic Mifepristone as White House Cites Legal Obligation

FDA Escalates Crackdown on Drug Ads, Moves to Close ‘Adequate Provision’ Loophole